Yuxiong Feng

Dr. Yuxiong Feng


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
MFM. Feng
M. Feng
JJJoy Qiu Jin
Joy Qiu Jin
LXL. Xia
L. Xia
TXT. Xiao
T. Xiao
SMS. Mei
S. Mei
DZDi Zhu
Di Zhu
Pharmacological inhibition of β-catenin/BCL9 interaction modulates T reg cells and improves immunotherapy.

9 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LYLi-Xian Yang
Li-Xian Yang
CQChuangye Qi
Chuangye Qi
SLSi Lu
Si Lu
XYXiang-Shi Ye
Xiang-Shi Ye
PMParnaz Merikhian
Parnaz Merikhian
Yuxiong FengYuxiong Feng
Yuxiong Feng
Liver fibrosis is a critical liver disease that can progress to more severe manifestations, such as cirrhosis, yet no effective targeted therapies are available. Here, we identify that ATF4, a master transcription factor in ER stress response, promotes liver fibrosis by facilitating a stress response-independent epigenetic program in hepatic stellate cells (HSCs). Unlike its canonical role in regulating UPR genes during ER stress, ATF4 activates epithelial-mesenchymal transition (EMT) gene transcription under fibrogenic conditions. HSC-specific depletion of ATF4 suppresses liver fibrosis in vivo. Mechanistically, TGFβ resets ATF4 to orchestrate a unique enhancer program for the transcriptional activation of pro-fibrotic EMT genes. Analysis of human data confirms a strong correlation between HSC ATF4 expression and liver fibrosis progression. Importantly, a small molecule inhibitor targeting ATF4 translation effectively mitigates liver fibrosis. Together, our findings identify a mechanism promoting liver fibrosis and reveal new opportunities for treating this otherwise non-targetable disease.

10 February 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
JZJiang-Sha Zhao
Jiang-Sha Zhao
SSShuo Shi
Shuo Shi
HQHai-Yan Qu
Hai-Yan Qu
ZKZuzana Keckesova
Zuzana Keckesova
ZCZi-Jian Cao
Zi-Jian Cao
Yuxiong FengYuxiong Feng
Yuxiong Feng

10 January 2025 in Science Advances
Verified
Journal Article
Open access
ZCZi-Jian Cao
Zi-Jian Cao
JYJia You
Jia You
YFYu-Meng Fan
Yu-Meng Fan
JYJia-Ying Yang
Jia-Ying Yang
JSJirui Sun
Jirui Sun
Yuxiong FengYuxiong Feng
Yuxiong Feng
The unfolded protein response (UPR) pathway is crucial for tumorigenesis, mainly by regulating cancer cell stress responses and survival. However, whether UPR factors facilitate cell-cell communication between cancer cells and immune cells to drive cancer progression remains unclear. We found that adenosine 3′,5′-monophosphate response element–binding protein 3–like protein 2 (CREB3L2), a noncanonical UPR factor, is overexpressed and activated in triple-negative breast cancer, where its cleavage releases a C-terminal fragment that activates the Hedgehog pathway in neighboring CD8+ T cells. The enhanced Hedgehog pathway represses CD8+ T cell activation and inhibits its cytotoxic effects. Consequently, overexpression of CREB3L2 not only promotes tumor growth but also causes resistance to immune checkpoint blockade (ICB). Inhibition of the Hedgehog pathway impedes the growth of CREB3L2-overexpressed tumors and sensitizes them to ICB therapy. In summary, we identified a previously unidentified mechanism by which the UPR pathway dictates cross-talk between cancer cells and immune cells, providing important anticancer therapeutic opportunities.

18 January 2024 in Journal of the National Cancer Center
Verified
Journal Article
Open access
LCLiang'En Chen
Liang'En Chen
XYXiangshi Ye
Xiangshi Ye
LYLixian Yang
Lixian Yang
JZJiangsha Zhao
Jiangsha Zhao
JYJia You
Jia You
Yuxiong FengYuxiong Feng
Yuxiong Feng
Hepatic stellate cells (HSCs), a distinct category of non-parenchymal cells in the liver, are critical for liver homeostasis. In healthy livers, HSCs remain non-proliferative and quiescent. However, under conditions of acute or chronic liver damage, HSCs are activated and participate in the progression and regulation of liver diseases such as liver fibrosis, cirrhosis, and liver cancer. Fatty liver diseases (FLD), including nonalcoholic (NAFLD) and alcohol-related (ALD), are common chronic inflammatory conditions of the liver. These diseases, often resulting from multiple metabolic disorders, can progress through a sequence of inflammation, fibrosis, and ultimately, cancer. In this review, we focused on the activation and regulatory mechanism of HSCs in the context of FLD. We summarized the molecular pathways of activated HSCs (aHSCs) in mediating FLD and their role in promoting liver tumor development from the perspectives of cell proliferation, invasion, metastasis, angiogenesis, immunosuppression, and chemo-resistance. We aimed to offer an in-depth discussion on the reciprocal regulatory interactions between FLD and HSC activation, providing new insights for researchers in this field.

3 July 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
TWTao Wang
Tao Wang
LFLimin Feng
Limin Feng
ZSZhong Shi
Zhong Shi
LYLixian Yang
Lixian Yang
XYXiaofu Yu
Xiaofu Yu
WWweilin wang
weilin wang
Metastasis is the primary cause of death of hepatocellular carcinoma (HCC), while the mechanism underlying this severe disease remains largely unclear. The Kruppel‐like factor (KLF) family is one of the largest transcription factor families that control multiple physiologic and pathologic processes by governing the cellular transcriptome. To identify metastatic regulators of HCC, we conducted gene expression profiling on the MHCC97 cell series, a set of subclones of the original MHCC97 that was established by in vivo metastasis selection therefore harbouring differential metastatic capacities. We found that the expression of KLF9, a member of the KLF family, was dramatically repressed in the metastatic progeny clone of the MHCC97 cells. Functional studies revealed overexpression of KLF9 suppressed HCC migration in vitro and metastasis in vivo, while knockdown of KLF9 was sufficient to promote cell migration and metastasis accordingly. Mechanistically, we found the expression of KLF9 can reverse the pro‐metastatic epithelial‐mesenchymal transition (EMT) program via direct binding to the promoter regions of essential mesenchymal genes, thus repressing their expression. Interestingly, we further revealed that KLF9 was, in turn, directly suppressed by a mesenchymal transcription factor Slug, suggesting an intriguing negative feedback loop between KLF9 and the EMT program. Using clinical samples, we found that KLF9 was not only downregulated in HCC tissue compared to its normal counterparts but also further reduced in the HCC samples of whom had developed metastatic lesions. Together, we established a critical transcription factor that represses HCC metastasis, which is clinically and mechanically significant in HCC therapies.